Setiptiline (brand name Tecipul), also known as teciptiline, is a tetracyclic antidepressant (TeCA) that acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). It was launched in 1989 for the treatment of depression in Japan by Mochida.

Setiptiline acts as a norepinephrine reuptake inhibitor, α₂-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT₂ subtypes,^{[citation needed]} as well as an H₁ receptor inverse agonist/antihistamine.^{[additional citation(s) needed]}

Setiptiline has a tetracyclic structure and is a close analogue of mianserin and mirtazapine, with setiptiline being delta(13b,4a),4a-carba-mianserin, and mirtazapine being 6-azamianserin.